![](/img/cover-not-exists.png)
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Goldberg, Sarah B, Schalper, Kurt A, Gettinger, Scott N, Mahajan, Amit, Herbst, Roy S, Chiang, Anne C, Lilenbaum, Rogerio, Wilson, Frederick H, Omay, Sacit Bulent, Yu, James B, Jilaveanu, Lucia, Tran,Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(20)30111-X
Date:
April, 2020
File:
PDF, 370 KB
english, 2020